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Introduction: Among the Big Five personality dimensions,
neuroticism has the strongest phenotypic as well as genotypic
correlations with lifetime major depression [1]. Previous genome-
wide association studies (GWAS) have applied SNP (single
nucleotide polymorphism)-based and gene-based tests to find
SNPs and genes in the background of neuroticism. However, in
those GWAS implementing gene-based tests, only onemethodwas
used.
Aim: In the present study, we conducted a GWAS on
neuroticism, both with SNP-based and with five distinct gene-
based tests.
Methods: Among a European white sample (N = 1770)
recruited in Budapest and Manchester, linear regression models
were run with each of the genome-wide genotyped 86,232 SNPs,
gender, age and the top ten principal components of the genome as
predictor variables, and neuroticism as the outcome. The yielded
SNP-based results then served as the input of the gene-based
GATES test. False discovery rate (FDR) method was used to
correct for multiple testing both at the SNP- and the gene-level,
with an error rate of 0.05. As post hoc tests without correction, four
additional gene-based tests were implemented according to
FORGE and SETSCREEN methods.
Results: 63,326 SNPs (64.46% of all) reside within genes, and
18,264 genes were identified. None of the SNPs or genes survives
the FDR correction. However, among the more than fifty genes
identified as candidates in previous neuroticism GWAS studies
either by a gene-based test or by locating any significant SNP into
a gene, we found that TACC2 (transforming acidic coiled-coil
containing protein 2) and SORCS3 (sortilin related VPS10 domain
containing receptor 3) genes are nominally significant (p ≤ 0.05)
to neuroticism in our study (Table 1). Nonetheless, TACC2 does
not show any significant (p ≤ 0.05) association with neuroticism
according to our post hoc gene-based tests, but the effect of
SORCS3 is significant in all of the four tests (Table 1).
Conclusion:Our GWAS study is the first one to report the gene-
level association of the SORCS3 gene with neuroticism, since the
original GWAS from which we chose this gene for replication did
not use a gene-based, but only a SNP-based approach [2].
Moreover, we further underpinned this gene-personality associ-
ation with four additional methods. SORCS3 SNPs have been
reported to be associated with Alzheimer’s disease, and the
expression level of this gene was lower in Alzheimer’s patients’
than in controls’ amygdala, but there was no such between-group
difference in occipital lobe or cerebellum [3]. Given the well-
grounded importance of the amygdala in depression risk and
neuroticism, further studies are needed to elucidate the precise role
of the SORCS3 gene and SORCS3 protein in neuroticism and
depression, and to reveal whether or not their association with
Alzheimer’s disease is mediated by this personality trait.
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Table 1. (Abstract P.1.a.005) Gene-based methods to assess the association of neuroticism with two genes reported in previous GWAS.
GATES method Post hoc tests
Gene Nominal P value FDR-corrected P value FORGE PSidak FORGE Zfix SETSCREEN P1 SETSCREEN P2
TACC2 0.0449 0.9696 0.9089 0.9857 0.9599 0.9698
SORCS3 0.0130 0.9296 0.0201 0.0106 0.0177 0.0437
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Background: Nowadays the problem of antidepressant therapy in
unipolar depression is considered important and the question of
treatment and prophylactics is extensively discussed in psychiatry.
Up-to-date information about biological markers which allows to
predict therapy response, remission and side effects is not
numerous [1,2]. The latest data consider the role of dopamine
transporter DAT1 coded by SLC6A3 gene in the pathogenesis of
depressive disorders, but results remain inconsistent [3,4]. In view
of these recent data SLC6A3 gene is a possible candidate for
pharmacogenetics studies.
Aim of the study: The aim of the research was to investigate the
association of single nucleotide polymorphisms (SNPs) of
SLC6A3 gene, encoding dopamine transporter DAT1, with
remission and antidepressant therapy response in patients with
depressive disorders.
Materials and methods: 171 patients (96 patients with
depressive episode (ICD-10: F32), 75 patients with recurrent
depressive disorder (ICD-10: F33), 35 male and 136 female in age
between 20 and 60 years) were included in the study.
Antidepressant therapy response on the 14th and 28th day of
therapy was evaluated using Clinical Global Impression –
Improvement scale (CGI-I). Remission was assessed by
Hamilton Depressive Rating Scale 17 (HDRS-17): score ≤7 for
remitters. 12 SNPs (rs3756450, rs2550956, rs6347, rs2617605,
rs3863145, rs250686, rs464049, rs4975646, rs1048953,
rs11133767, rs27048, rs40184) of SLC6A3 gene were genotyped.
The chi-squared test was used for Hardy-Weinberg equilibrium and
for between-groups of remitters and non-remitters comparison of
genotypic and allelic frequencies. Median and quartiles for CGI-I
scale scores were calculated. Between-group differences were
evaluated using Kruskal–Wallis H test. Statistical analyses were
performed using the SPSS software, release 20.0, for Windows. p
values less than 0.05 were considered as significant.
Results: Correlation between CGI-I scale scores and SNPs of
SLC6A3 gene were studied. Patients with genotype T/T of SNP
rs464049 had a higher score of CGI-I scale on 28th day of
therapy (2.0 (1.0–2.0)) compared to patients with С/С (1.0 (1.0–
2.0)) and С/Т (1.0 (1.0–2.0)) genotypes (р = 0.045). The highest
score of CGI-I scale on 28th day of treatment (2.0 (1.0–2.0)) was
found in patients with T/T genotype of SNP rs1048953 (р =
0.011). Genotypic and allelic frequencies of SNPs of SLC6A3
gene in groups of remitters and non-remitters were studied.
Distribution of genotypes was in agreement with Hardy-
Weinberg equilibrium. Genotype C/C of SNP rs2550956 was
not observed in the group of non-remitters and its frequency
in the group of remitters was 9.3% (р = 0.027; OR = 8.93, 95%Cl
= 0.52–152.39). Frequency of G/G genotype of SNP rs6347
was higher in the group of non-remitters (19.1%) compared to
the group of remitters (6.9%) (р = 0.041; OR = 3.19, 95%Cl =
1.19–8.53). Frequency of allele G was higher in the group of
non-remitters (23.8%) comparing to the group of remitters
(15.0%) (р = 0.050; OR = 1.77, 95%Cl = 0.98–3.19).
Conclusion: We have found an association between SNPs
rs464049, rs1048953 and antidepressant therapy response.
Asscociation of SNPs rs2550956, rs6347 and remission has
been observed. It is possible that SNPs rs464049, rs1048953 and
rs6347 are associated with blunted therapy response.
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Schizophrenia is a severe mental disorder affecting around 1% of
the population. This disease has a complex aetiology, involving
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